Patents by Inventor Susan Macdonald

Susan Macdonald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OPHTHALMIC FORMULATIONS AND USES THEREOF
    Publication number: 20240139173
    Abstract: The present invention provides a reproxalap ophthalmic solution, and methods of using the same for treating a disease or disorder such as allergic conjunctivitis.
    Type: Application
    Filed: September 12, 2023
    Publication date: May 2, 2024
    Inventors: David CLARK, Susan MACDONALD, Stephen Gitu MACHATHA, Lise Lund KJEMS
  • DEUTERATED COMPOUNDS AND USES THEREOF
    Publication number: 20240132451
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: November 8, 2023
    Publication date: April 25, 2024
    Inventors: Todd BRADY, Scott Young, William A. Kinney, Susan MACDONALD
  • Human antibodies to artemin and methods of use thereof
    Patent number: 11926661
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind to human artemin. Methods for using anti-artemin antibodies and antigen-binding fragments are also provided.
    Type: Grant
    Filed: April 19, 2022
    Date of Patent: March 12, 2024
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Susan D. Croll, Lynn MacDonald, Andrew J. Murphy
  • Deuterated compounds and uses thereof
    Patent number: 11845722
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: September 2, 2022
    Date of Patent: December 19, 2023
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Susan Macdonald
  • Ophthalmic formulations and uses thereof
    Patent number: 11786518
    Abstract: The present invention provides a reproxalap ophthalmic solution, and methods of using the same for treating a disease or disorder such as allergic conjunctivitis.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: October 17, 2023
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: David Clark, Susan Macdonald, Stephen Gitu Machatha, Lise Lund Kjems
  • TREATMENT OF INFLAMMATORY DISORDERS
    Publication number: 20230293527
    Abstract: The present disclosure provides compounds and methods of use thereof for treating inflammatory diseases or disorders.
    Type: Application
    Filed: May 26, 2023
    Publication date: September 21, 2023
    Inventors: Susan MACDONALD, Adna HALILOVIC
  • TREATMENT OF INFLAMMATORY DISORDERS
    Publication number: 20230248727
    Abstract: The present disclosure provides compounds and methods of use thereof for treating inflammatory diseases or disorders.
    Type: Application
    Filed: January 3, 2023
    Publication date: August 10, 2023
    Inventors: Susan Macdonald, Adna Halilovic
  • DEUTERATED COMPOUNDS AND USES THEREOF
    Publication number: 20230174491
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: September 2, 2022
    Publication date: June 8, 2023
    Inventors: Todd BRADY, Scott Young, William A. Kinney, Susan Macdonald
  • Treatment of inflammatory disorders
    Patent number: 11583529
    Abstract: The present disclosure provides compounds and methods of use thereof for treating inflammatory diseases or disorders.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: February 21, 2023
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Susan Macdonald, Adna Halilovic
  • Deuterated compounds and uses thereof
    Patent number: 11459300
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: October 4, 2022
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Susan Macdonald
  • INJECTABLE FORMULATIONS
    Publication number: 20220133697
    Abstract: The present disclosure relates to therapeutic compounds and formulations for treating, reducing the risk of, or for preventing a disease, disorder, or condition characterized by the presence of toxic aldehydes.
    Type: Application
    Filed: December 5, 2019
    Publication date: May 5, 2022
    Inventors: Stephen Gitu MACHATHA, Susan MACDONALD
  • FORMULATIONS FOR TREATMENT OF DRY EYE DISEASE
    Publication number: 20220133629
    Abstract: The present invention provides a reproxalap ophthalmic solution, and methods of using the same for treating dry eye disease.
    Type: Application
    Filed: October 12, 2021
    Publication date: May 5, 2022
    Inventors: David CLARK, Todd BRADY, Susan MACDONALD, Stephen Gitu MACHATHA
  • Formulations for treatment of dry eye disease
    Patent number: 11197821
    Abstract: The present invention provides a reproxalap ophthalmic solution, and methods of using the same for treating dry eye disease.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: December 14, 2021
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: David Clark, Todd Brady, Susan Macdonald, Stephen Gitu Machatha
  • TREATMENT OF INFLAMMATORY DISORDERS
    Publication number: 20210353628
    Abstract: The present disclosure provides compounds and methods of use thereof for treating inflammatory diseases or disorders.
    Type: Application
    Filed: May 24, 2021
    Publication date: November 18, 2021
    Inventors: Susan Macdonald, Adna Halilovic
  • DEUTERATED COMPOUNDS AND USES THEREOF
    Publication number: 20210347735
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: May 19, 2021
    Publication date: November 11, 2021
    Inventors: Todd Brady, Scott Young, William A. Kinney, Susan Macdonald
  • CONTACT LENS SOLUTIONS AND KITS
    Publication number: 20210317385
    Abstract: The present disclosure relates to contact lens solution comprising cyclodextrin, ophthalmic solutions comprising cy-clodextrin for treating disorders or conditions associated with wearing of contact lenses, methods of treating such disorders or conditions using the ophthalmic cyclodextrin solutions, and kits and combination products thereof.
    Type: Application
    Filed: October 2, 2019
    Publication date: October 14, 2021
    Inventors: Susan MACDONALD, Stephen Gitu MACHATHA
  • Deuterated compounds and uses thereof
    Patent number: 11046650
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: June 29, 2021
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Susan Macdonald
  • Treatment of inflammatory disorders
    Patent number: 11040039
    Abstract: The present disclosure provides compounds and methods of use thereof for treating inflammatory diseases or disorders.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: June 22, 2021
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Susan Macdonald, Adna Halilovic
  • OPHTHALMIC FORMULATIONS AND USES THEREOF
    Publication number: 20200323841
    Abstract: The present invention provides a reproxalap ophthalmic solution, and methods of using the same for treating a disease or disorder such as allergic conjunctivitis.
    Type: Application
    Filed: March 20, 2020
    Publication date: October 15, 2020
    Inventors: David CLARK, Susan MACDONALD, Stephen Gitu MACHATHA, Lise Lund KJEMS
  • DEUTERATED COMPOUNDS AND USES THEREOF
    Publication number: 20200199075
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: December 19, 2019
    Publication date: June 25, 2020
    Inventors: Todd Brady, Scott Young, William A. Kinney, Susan Macdonald